![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that are psychologically and physiologically well tolerated. With appropriate care, this study supports the viability of functional magnetic resonance imaging work with psilocybin.
References
| Dittrich, A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl. 2): 80–84. Google Scholar | Crossref | Medline | ISI | |
| Gouzoulis-Mayfrank, E, Schreckenberger, M, Sabri, O (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F] FDG. Neuropsychopharmacology 20: 565–581. Google Scholar | |
| Griffiths, RR, Richards, WA, McCann, U, Jesse, R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268–283. Google Scholar | Crossref | Medline | ISI | |
| Grinspoon, L, Bakalar, JB (1979) Psychedelic drugs reconsidered. New York: Basic Books. Google Scholar | |
| Hasler, F, Bourquin, D, Brenneisen, R, Bär, T, Vollenweider, FX (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72: 175–184. Google Scholar | Crossref | Medline | |
| Hasler, F, Grimberg, U, Benz, MA, Huber, T, Vollenweider, FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a doubleblind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 172: 145–156. Google Scholar | Crossref | Medline | ISI | |
| Hofmann, A, Frey, A, Ott, H, Petr-Zilker, T, Troxler, F (1958) Elucidation of the structure and the synthesis of psilocybin. Experientia 14: 397–399. Google Scholar | Crossref | Medline | |
| Hofmann, A, Heim, R, Barck, A (1959) Psilocybin and psilocin. Helv Chim Acta 42: 1557–1572. Google Scholar | Crossref | ISI | |
| Johnson, M, Richards, W, Griffiths, R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22: 603–620. Google Scholar | SAGE Journals | ISI | |
| Lee, AA, Shlain, B (1985) Acid dreams. The complete social history of LSD. New York: Grove Press. Google Scholar | |
| Leuner, H (1963) Psychotherapy with hallucinogens. A clinical report with special reference to the revival of emotional phases of childhood. In: Crockett, R, Sandison, R, Walk, A Hallucinogenic drugs and their psychotherapeutic use London: H.K.Lewis67–73. Google Scholar | |
| Nichols, DE (2004) Hallucinogens. Pharmacol Ther 101: 131–181. Google Scholar | Crossref | Medline | ISI | |
| Osmond, H (1957) A review of the clinical effects of psychotomimetic Agents. Ann N Y Acad Sci 66: 418–434. Google Scholar | Crossref | Medline | ISI | |
| Spencer, AM (1966) Lysergic acid diethylamide. Br Med J 2: 49–49. Google Scholar | Crossref | Medline | |
| Vollenweider, FX, Leenders, KL, Scharfetter, C, Maguire, P, Stadelmann, O, Angst, J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357–372. Google Scholar | Crossref | Medline | ISI |
